Akebia Therapeutics (AKBA) Competitors $2.96 -0.06 (-1.99%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.98 +0.02 (+0.51%) As of 09/5/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. TLX, SRRK, ARWR, VKTX, AMRX, XENE, KYMR, CRNX, RARE, and MORShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Telix Pharmaceuticals (TLX), Scholar Rock (SRRK), Arrowhead Pharmaceuticals (ARWR), Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Its Competitors Telix Pharmaceuticals Scholar Rock Arrowhead Pharmaceuticals Viking Therapeutics Amneal Pharmaceuticals Xenon Pharmaceuticals Kymera Therapeutics Crinetics Pharmaceuticals Ultragenyx Pharmaceutical MorphoSys Telix Pharmaceuticals (NASDAQ:TLX) and Akebia Therapeutics (NASDAQ:AKBA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership. Which has higher earnings & valuation, TLX or AKBA? Telix Pharmaceuticals has higher revenue and earnings than Akebia Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M5.93$32.93MN/AN/AAkebia Therapeutics$203.73M3.85-$69.41M-$0.17-17.41 Is TLX or AKBA more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -17.91%. Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Akebia Therapeutics -17.91%N/A -13.47% Do insiders & institutionals hold more shares of TLX or AKBA? 33.9% of Akebia Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend TLX or AKBA? Telix Pharmaceuticals presently has a consensus price target of $22.33, suggesting a potential upside of 146.50%. Akebia Therapeutics has a consensus price target of $6.75, suggesting a potential upside of 128.04%. Given Telix Pharmaceuticals' higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Akebia Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer TLX or AKBA? In the previous week, Telix Pharmaceuticals had 4 more articles in the media than Akebia Therapeutics. MarketBeat recorded 12 mentions for Telix Pharmaceuticals and 8 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.18 beat Telix Pharmaceuticals' score of 0.02 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Akebia Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTelix Pharmaceuticals beats Akebia Therapeutics on 7 of the 12 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$784.83M$2.84B$5.79B$9.92BDividend YieldN/A50.34%6.71%4.52%P/E Ratio-17.4123.3476.1526.13Price / Sales3.85571.71463.3081.99Price / CashN/A167.8736.9659.04Price / Book-12.875.5011.486.09Net Income-$69.41M$32.95M$3.29B$266.51M7 Day Performance-5.73%2.88%1.27%0.46%1 Month Performance-21.90%8.63%7.94%4.59%1 Year Performance119.26%1.88%62.94%26.04% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics3.7142 of 5 stars$2.96-2.0%$6.75+128.0%+114.5%$784.83M$203.73M-17.41430Positive NewsAnalyst UpgradeTLXTelix PharmaceuticalsN/A$9.55-5.9%$22.33+133.9%N/A$3.23B$516.72M0.00N/AGap DownHigh Trading VolumeSRRKScholar Rock4.5144 of 5 stars$32.65-1.9%$45.75+40.1%+265.7%$3.14BN/A-11.22140News CoveragePositive NewsARWRArrowhead Pharmaceuticals3.9464 of 5 stars$22.03-1.4%$43.14+95.8%+25.1%$3.05B$3.55M-17.21400Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionVKTXViking Therapeutics4.3135 of 5 stars$27.05-1.9%$86.92+221.3%-51.3%$3.04BN/A-17.6820Positive NewsAMRXAmneal Pharmaceuticals3.4839 of 5 stars$9.56+0.1%$11.60+21.3%+13.8%$3.00B$2.79B956.967,600News CoveragePositive NewsXENEXenon Pharmaceuticals2.8072 of 5 stars$38.71+0.3%$53.20+37.4%-1.6%$2.98B$9.43M-10.90210News CoveragePositive NewsAnalyst ForecastOptions VolumeKYMRKymera Therapeutics3.2685 of 5 stars$41.20-1.3%$58.76+42.6%-6.6%$2.95B$44.71M-11.87170News CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.9175 of 5 stars$30.99+1.1%$68.86+122.2%-30.1%$2.92B$1.39M-7.54210News CoveragePositive NewsRAREUltragenyx Pharmaceutical4.3837 of 5 stars$29.96-1.1%$81.50+172.0%-43.6%$2.89B$560.23M-5.421,310News CoveragePositive NewsAnalyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies TLX Alternatives SRRK Alternatives ARWR Alternatives VKTX Alternatives AMRX Alternatives XENE Alternatives KYMR Alternatives CRNX Alternatives RARE Alternatives MOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
